The Experts below are selected from a list of 936 Experts worldwide ranked by ideXlab platform
Bart C J M Fauser - One of the best experts on this subject based on the ideXlab platform.
-
nonsupplemented luteal phase characteristics after the administration of Recombinant human chorionic gonadotropin Recombinant Luteinizing Hormone or gonadotropin releasing Hormone gnrh agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with Recombinant follicle stimulating Hormone and gnrh antagonist cotreatment
The Journal of Clinical Endocrinology and Metabolism, 2003Co-Authors: Nicole G M Beckers, K Diedrich, R Felberbaum, Ernest Loumaye, Nick S Macklon, Marinus J C Eijkemans, Michael Ludwig, Shelly Bustion, Bart C J M FauserAbstract:Replacing GnRH agonist cotreatment for the prevention of a premature rise in LH during ovarian stimulation for in vitro fertilization (IVF) by the late follicular phase administration of GnRH antagonist may render supplementation of the luteal phase redundant, because of the known rapid recovery of pituitary function after antagonist cessation. This randomized two-center study was performed to compare nonsupplemented luteal phase characteristics after three different strategies for inducing final oocyte maturation. Forty patients underwent ovarian stimulation using Recombinant (r-)FSH (150 IU/d, fixed) combined with a GnRH antagonist (antide; 1 mg/d) during the late follicular phase. When at least one follicle above 18 mm was observed, patients were randomized to induce oocyte maturation by a single injection of either r-human (h)CG (250 microg) (n = 11), r-LH (1 mg) (n = 13), or GnRH agonist (triptorelin; 0.2 mg) (n = 15). Retrieved oocytes were fertilized by either IVF or intracytoplasmatic sperm injection, depending on sperm quality. Embryo transfer was performed 3-4 d after oocyte retrieval. No luteal support was provided. Serum concentrations of FSH, LH, estradiol (E(2)), progesterone (P), and hCG were assessed at fixed intervals during the follicular and luteal phase. The median duration of the luteal phase was 13, 10, and 9 d for the r-hCG, the r-LH, and the GnRH agonist group, respectively (P = 0.005). The median area under the curve per day (from 4 d post randomization until the onset of menses) for LH was 0.50, 2.34, and 1.07 for the r-hCG, the r-LH, and the GnRH agonist group, respectively (P = 0.001). The median area under the curve per day for P was 269 vs. 41 and 16 for the r-hCG, the r-LH, and the GnRH agonist group, respectively (P < 0.001). Low pregnancy rates (overall, 7.5%; range, 0-18% per started cycle) were observed in all groups. In conclusion, the nonsupplemented luteal phase was insufficient in all three groups. In the patients receiving r-hCG, the luteal phase was less disturbed, compared with both other groups, presumably because of prolonged clearance of hCG from the circulation and the resulting extended support of the corpus luteum. Despite high P and E(2) concentrations during the early luteal phase in all three groups, luteolysis started prematurely, presumably because of excessive negative steroid feedback resulting in suppressed pituitary LH release. Hence, support of corpus luteum function remains mandatory after ovarian stimulation for IVF with GnRH antagonist cotreatment.
-
nonsupplemented luteal phase characteristics after the administration of Recombinant human chorionic gonadotropin Recombinant Luteinizing Hormone or gonadotropin releasing Hormone gnrh agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with Recombinant follicle stimulating Hormone and gnrh antagonist cotreatment
The Journal of Clinical Endocrinology and Metabolism, 2003Co-Authors: Nicole G M Beckers, K Diedrich, R Felberbaum, Ernest Loumaye, Nick S Macklon, Marinus J C Eijkemans, Michael Ludwig, Shelly Bustion, Bart C J M FauserAbstract:Replacing GnRH agonist cotreatment for the prevention of a premature rise in LH during ovarian stimulation for in vitro fertilization (IVF) by the late follicular phase administration of GnRH antagonist may render supplementation of the luteal phase redundant, because of the known rapid recovery of pituitary function after antagonist cessation. This randomized two-center study was performed to compare nonsupplemented luteal phase characteristics after three different strategies for inducing final oocyte maturation. Forty patients underwent ovarian stimulation using Recombinant (r-)FSH (150 IU/d, fixed) combined with a GnRH antagonist (antide; 1 mg/d) during the late follicular phase. When at least one follicle above 18 mm was observed, patients were randomized to induce oocyte maturation by a single injection of either r-human (h)CG (250 μg) (n = 11), r-LH (1 mg) (n = 13), or GnRH agonist (triptorelin; 0.2 mg) (n = 15). Retrieved oocytes were fertilized by either IVF or intracytoplasmatic sperm injection,...
R Felberbaum - One of the best experts on this subject based on the ideXlab platform.
-
Recombinant Luteinizing Hormone supplementation to Recombinant follicle stimulating Hormone induced ovarian hyperstimulation in the gnrh antagonist multiple dose protocol
Human Reproduction, 2005Co-Authors: G Griesinger, A Schultzemosgau, Konstantinos Dafopoulos, A Schroeder, A Schroer, S Von Otte, D Hornung, K Diedrich, R FelberbaumAbstract:BACKGROUND: Suppression of endogenous LH production by mid-follicular phase GnRH-antagonist administration in controlled ovarian hyperstimulation protocol using Recombinant (rec) FSH preparations void of LH activity may potentially affect ovarian response and the outcome of IVF treatment. The present study prospectively assessed the effect of using a combination of recFSH and recLH on ovarian stimulation parameters and treatment outcome in a fixed GnRH-antagonist multiple dose protocol. METHODS: 127 infertile patients with an indication for IVF or ICSI were recruited and randomized (using sealed envelopes) to receive a starting dose of either 150 IU recFSH (follitropin a) or 150 IU recFSH plus 75 IU recLH (lutropin a) for ovarian hyperstimulation. GnRHantagonist (Cetrorelix) 0.25 mg was administered daily from stimulation day 6 onwards up to and including the day of the administration of Recombinant HCG (chorion gonadotropin a). Gonadotropin dose adjustments were allowed from stimulation day 6 onwards, HCG was administered as soon as three follicles $18 mm were present. The primary outcome parameter was treatment duration until administration of HCG. RESULTS: Exogenous LH did not shorten the time necessary to reach ovulation induction criteria. Serum estradiol (E2) and LH levels were significantly higher on the day of HCG administration in the recLH-supplemented group (1924.7 6 1256.4 vs 1488.3 6 824.0 pg/ml, P< 0.03), and 2.1 6 1.4 vs 1.4 6 1.5 IU/l, P< 0.01, respectively). CONCLUSIONS: Except for higher E2 and LH levels on the day of HCG administration, no positive trend in favour of additional LH was found as defined by treatment outcome parameters.
-
nonsupplemented luteal phase characteristics after the administration of Recombinant human chorionic gonadotropin Recombinant Luteinizing Hormone or gonadotropin releasing Hormone gnrh agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with Recombinant follicle stimulating Hormone and gnrh antagonist cotreatment
The Journal of Clinical Endocrinology and Metabolism, 2003Co-Authors: Nicole G M Beckers, K Diedrich, R Felberbaum, Ernest Loumaye, Nick S Macklon, Marinus J C Eijkemans, Michael Ludwig, Shelly Bustion, Bart C J M FauserAbstract:Replacing GnRH agonist cotreatment for the prevention of a premature rise in LH during ovarian stimulation for in vitro fertilization (IVF) by the late follicular phase administration of GnRH antagonist may render supplementation of the luteal phase redundant, because of the known rapid recovery of pituitary function after antagonist cessation. This randomized two-center study was performed to compare nonsupplemented luteal phase characteristics after three different strategies for inducing final oocyte maturation. Forty patients underwent ovarian stimulation using Recombinant (r-)FSH (150 IU/d, fixed) combined with a GnRH antagonist (antide; 1 mg/d) during the late follicular phase. When at least one follicle above 18 mm was observed, patients were randomized to induce oocyte maturation by a single injection of either r-human (h)CG (250 microg) (n = 11), r-LH (1 mg) (n = 13), or GnRH agonist (triptorelin; 0.2 mg) (n = 15). Retrieved oocytes were fertilized by either IVF or intracytoplasmatic sperm injection, depending on sperm quality. Embryo transfer was performed 3-4 d after oocyte retrieval. No luteal support was provided. Serum concentrations of FSH, LH, estradiol (E(2)), progesterone (P), and hCG were assessed at fixed intervals during the follicular and luteal phase. The median duration of the luteal phase was 13, 10, and 9 d for the r-hCG, the r-LH, and the GnRH agonist group, respectively (P = 0.005). The median area under the curve per day (from 4 d post randomization until the onset of menses) for LH was 0.50, 2.34, and 1.07 for the r-hCG, the r-LH, and the GnRH agonist group, respectively (P = 0.001). The median area under the curve per day for P was 269 vs. 41 and 16 for the r-hCG, the r-LH, and the GnRH agonist group, respectively (P < 0.001). Low pregnancy rates (overall, 7.5%; range, 0-18% per started cycle) were observed in all groups. In conclusion, the nonsupplemented luteal phase was insufficient in all three groups. In the patients receiving r-hCG, the luteal phase was less disturbed, compared with both other groups, presumably because of prolonged clearance of hCG from the circulation and the resulting extended support of the corpus luteum. Despite high P and E(2) concentrations during the early luteal phase in all three groups, luteolysis started prematurely, presumably because of excessive negative steroid feedback resulting in suppressed pituitary LH release. Hence, support of corpus luteum function remains mandatory after ovarian stimulation for IVF with GnRH antagonist cotreatment.
-
nonsupplemented luteal phase characteristics after the administration of Recombinant human chorionic gonadotropin Recombinant Luteinizing Hormone or gonadotropin releasing Hormone gnrh agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with Recombinant follicle stimulating Hormone and gnrh antagonist cotreatment
The Journal of Clinical Endocrinology and Metabolism, 2003Co-Authors: Nicole G M Beckers, K Diedrich, R Felberbaum, Ernest Loumaye, Nick S Macklon, Marinus J C Eijkemans, Michael Ludwig, Shelly Bustion, Bart C J M FauserAbstract:Replacing GnRH agonist cotreatment for the prevention of a premature rise in LH during ovarian stimulation for in vitro fertilization (IVF) by the late follicular phase administration of GnRH antagonist may render supplementation of the luteal phase redundant, because of the known rapid recovery of pituitary function after antagonist cessation. This randomized two-center study was performed to compare nonsupplemented luteal phase characteristics after three different strategies for inducing final oocyte maturation. Forty patients underwent ovarian stimulation using Recombinant (r-)FSH (150 IU/d, fixed) combined with a GnRH antagonist (antide; 1 mg/d) during the late follicular phase. When at least one follicle above 18 mm was observed, patients were randomized to induce oocyte maturation by a single injection of either r-human (h)CG (250 μg) (n = 11), r-LH (1 mg) (n = 13), or GnRH agonist (triptorelin; 0.2 mg) (n = 15). Retrieved oocytes were fertilized by either IVF or intracytoplasmatic sperm injection,...
Ernest Loumaye - One of the best experts on this subject based on the ideXlab platform.
-
nonsupplemented luteal phase characteristics after the administration of Recombinant human chorionic gonadotropin Recombinant Luteinizing Hormone or gonadotropin releasing Hormone gnrh agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with Recombinant follicle stimulating Hormone and gnrh antagonist cotreatment
The Journal of Clinical Endocrinology and Metabolism, 2003Co-Authors: Nicole G M Beckers, K Diedrich, R Felberbaum, Ernest Loumaye, Nick S Macklon, Marinus J C Eijkemans, Michael Ludwig, Shelly Bustion, Bart C J M FauserAbstract:Replacing GnRH agonist cotreatment for the prevention of a premature rise in LH during ovarian stimulation for in vitro fertilization (IVF) by the late follicular phase administration of GnRH antagonist may render supplementation of the luteal phase redundant, because of the known rapid recovery of pituitary function after antagonist cessation. This randomized two-center study was performed to compare nonsupplemented luteal phase characteristics after three different strategies for inducing final oocyte maturation. Forty patients underwent ovarian stimulation using Recombinant (r-)FSH (150 IU/d, fixed) combined with a GnRH antagonist (antide; 1 mg/d) during the late follicular phase. When at least one follicle above 18 mm was observed, patients were randomized to induce oocyte maturation by a single injection of either r-human (h)CG (250 μg) (n = 11), r-LH (1 mg) (n = 13), or GnRH agonist (triptorelin; 0.2 mg) (n = 15). Retrieved oocytes were fertilized by either IVF or intracytoplasmatic sperm injection,...
-
nonsupplemented luteal phase characteristics after the administration of Recombinant human chorionic gonadotropin Recombinant Luteinizing Hormone or gonadotropin releasing Hormone gnrh agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with Recombinant follicle stimulating Hormone and gnrh antagonist cotreatment
The Journal of Clinical Endocrinology and Metabolism, 2003Co-Authors: Nicole G M Beckers, K Diedrich, R Felberbaum, Ernest Loumaye, Nick S Macklon, Marinus J C Eijkemans, Michael Ludwig, Shelly Bustion, Bart C J M FauserAbstract:Replacing GnRH agonist cotreatment for the prevention of a premature rise in LH during ovarian stimulation for in vitro fertilization (IVF) by the late follicular phase administration of GnRH antagonist may render supplementation of the luteal phase redundant, because of the known rapid recovery of pituitary function after antagonist cessation. This randomized two-center study was performed to compare nonsupplemented luteal phase characteristics after three different strategies for inducing final oocyte maturation. Forty patients underwent ovarian stimulation using Recombinant (r-)FSH (150 IU/d, fixed) combined with a GnRH antagonist (antide; 1 mg/d) during the late follicular phase. When at least one follicle above 18 mm was observed, patients were randomized to induce oocyte maturation by a single injection of either r-human (h)CG (250 microg) (n = 11), r-LH (1 mg) (n = 13), or GnRH agonist (triptorelin; 0.2 mg) (n = 15). Retrieved oocytes were fertilized by either IVF or intracytoplasmatic sperm injection, depending on sperm quality. Embryo transfer was performed 3-4 d after oocyte retrieval. No luteal support was provided. Serum concentrations of FSH, LH, estradiol (E(2)), progesterone (P), and hCG were assessed at fixed intervals during the follicular and luteal phase. The median duration of the luteal phase was 13, 10, and 9 d for the r-hCG, the r-LH, and the GnRH agonist group, respectively (P = 0.005). The median area under the curve per day (from 4 d post randomization until the onset of menses) for LH was 0.50, 2.34, and 1.07 for the r-hCG, the r-LH, and the GnRH agonist group, respectively (P = 0.001). The median area under the curve per day for P was 269 vs. 41 and 16 for the r-hCG, the r-LH, and the GnRH agonist group, respectively (P < 0.001). Low pregnancy rates (overall, 7.5%; range, 0-18% per started cycle) were observed in all groups. In conclusion, the nonsupplemented luteal phase was insufficient in all three groups. In the patients receiving r-hCG, the luteal phase was less disturbed, compared with both other groups, presumably because of prolonged clearance of hCG from the circulation and the resulting extended support of the corpus luteum. Despite high P and E(2) concentrations during the early luteal phase in all three groups, luteolysis started prematurely, presumably because of excessive negative steroid feedback resulting in suppressed pituitary LH release. Hence, support of corpus luteum function remains mandatory after ovarian stimulation for IVF with GnRH antagonist cotreatment.
-
effects of human Recombinant Luteinizing Hormone and follicle stimulating Hormone in patients with acquired hypogonadotropic hypogonadism study of sertoli and leydig cell secretions and interactions
The Journal of Clinical Endocrinology and Metabolism, 2000Co-Authors: Jacques Young, Beatrice Couzinet, Philippe Chanson, Sylvie Brailly, Ernest Loumaye, Gilbert SchaisonAbstract:Experimental data suggest that FSH-stimulated Sertoli cells can enhance LH-induced Leydig cell testosterone (T) production. The function of Leydig and Sertoli cells can be selectively studied by using Recombinant human LH (rhLH) and Recombinant human FSH (rhFSH) in patients with complete gonadotropin deficiency. The aim of the present study was to assess the secretion of testicular T, estradiol (E2), and inhibin B and the physiological relevance of the Sertoli-Leydig cell interaction in man. For that purpose, six patients with acquired complete hypogonadotropic hypogonadism received the following treatments for three periods of 1 month in a random order: 1) rhLH, 900 IU/day sc; 2) rhFSH, 150 IU/day sc; and 3) combined rhLH/rhFSH treatments. Each treatment period was separated by a washout period of 15 days. Plasma LH, FSH, T, E2, and inhibin B were measured before and every 10 days during each treatment. During rhLH administration, mean plasma LH levels rose significantly from 0.4 ± 0.2 IU/L to 11.7 ± 1.2...
K Diedrich - One of the best experts on this subject based on the ideXlab platform.
-
Recombinant Luteinizing Hormone supplementation to Recombinant follicle stimulating Hormone induced ovarian hyperstimulation in the gnrh antagonist multiple dose protocol
Human Reproduction, 2005Co-Authors: G Griesinger, A Schultzemosgau, Konstantinos Dafopoulos, A Schroeder, A Schroer, S Von Otte, D Hornung, K Diedrich, R FelberbaumAbstract:BACKGROUND: Suppression of endogenous LH production by mid-follicular phase GnRH-antagonist administration in controlled ovarian hyperstimulation protocol using Recombinant (rec) FSH preparations void of LH activity may potentially affect ovarian response and the outcome of IVF treatment. The present study prospectively assessed the effect of using a combination of recFSH and recLH on ovarian stimulation parameters and treatment outcome in a fixed GnRH-antagonist multiple dose protocol. METHODS: 127 infertile patients with an indication for IVF or ICSI were recruited and randomized (using sealed envelopes) to receive a starting dose of either 150 IU recFSH (follitropin a) or 150 IU recFSH plus 75 IU recLH (lutropin a) for ovarian hyperstimulation. GnRHantagonist (Cetrorelix) 0.25 mg was administered daily from stimulation day 6 onwards up to and including the day of the administration of Recombinant HCG (chorion gonadotropin a). Gonadotropin dose adjustments were allowed from stimulation day 6 onwards, HCG was administered as soon as three follicles $18 mm were present. The primary outcome parameter was treatment duration until administration of HCG. RESULTS: Exogenous LH did not shorten the time necessary to reach ovulation induction criteria. Serum estradiol (E2) and LH levels were significantly higher on the day of HCG administration in the recLH-supplemented group (1924.7 6 1256.4 vs 1488.3 6 824.0 pg/ml, P< 0.03), and 2.1 6 1.4 vs 1.4 6 1.5 IU/l, P< 0.01, respectively). CONCLUSIONS: Except for higher E2 and LH levels on the day of HCG administration, no positive trend in favour of additional LH was found as defined by treatment outcome parameters.
-
nonsupplemented luteal phase characteristics after the administration of Recombinant human chorionic gonadotropin Recombinant Luteinizing Hormone or gonadotropin releasing Hormone gnrh agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with Recombinant follicle stimulating Hormone and gnrh antagonist cotreatment
The Journal of Clinical Endocrinology and Metabolism, 2003Co-Authors: Nicole G M Beckers, K Diedrich, R Felberbaum, Ernest Loumaye, Nick S Macklon, Marinus J C Eijkemans, Michael Ludwig, Shelly Bustion, Bart C J M FauserAbstract:Replacing GnRH agonist cotreatment for the prevention of a premature rise in LH during ovarian stimulation for in vitro fertilization (IVF) by the late follicular phase administration of GnRH antagonist may render supplementation of the luteal phase redundant, because of the known rapid recovery of pituitary function after antagonist cessation. This randomized two-center study was performed to compare nonsupplemented luteal phase characteristics after three different strategies for inducing final oocyte maturation. Forty patients underwent ovarian stimulation using Recombinant (r-)FSH (150 IU/d, fixed) combined with a GnRH antagonist (antide; 1 mg/d) during the late follicular phase. When at least one follicle above 18 mm was observed, patients were randomized to induce oocyte maturation by a single injection of either r-human (h)CG (250 microg) (n = 11), r-LH (1 mg) (n = 13), or GnRH agonist (triptorelin; 0.2 mg) (n = 15). Retrieved oocytes were fertilized by either IVF or intracytoplasmatic sperm injection, depending on sperm quality. Embryo transfer was performed 3-4 d after oocyte retrieval. No luteal support was provided. Serum concentrations of FSH, LH, estradiol (E(2)), progesterone (P), and hCG were assessed at fixed intervals during the follicular and luteal phase. The median duration of the luteal phase was 13, 10, and 9 d for the r-hCG, the r-LH, and the GnRH agonist group, respectively (P = 0.005). The median area under the curve per day (from 4 d post randomization until the onset of menses) for LH was 0.50, 2.34, and 1.07 for the r-hCG, the r-LH, and the GnRH agonist group, respectively (P = 0.001). The median area under the curve per day for P was 269 vs. 41 and 16 for the r-hCG, the r-LH, and the GnRH agonist group, respectively (P < 0.001). Low pregnancy rates (overall, 7.5%; range, 0-18% per started cycle) were observed in all groups. In conclusion, the nonsupplemented luteal phase was insufficient in all three groups. In the patients receiving r-hCG, the luteal phase was less disturbed, compared with both other groups, presumably because of prolonged clearance of hCG from the circulation and the resulting extended support of the corpus luteum. Despite high P and E(2) concentrations during the early luteal phase in all three groups, luteolysis started prematurely, presumably because of excessive negative steroid feedback resulting in suppressed pituitary LH release. Hence, support of corpus luteum function remains mandatory after ovarian stimulation for IVF with GnRH antagonist cotreatment.
-
nonsupplemented luteal phase characteristics after the administration of Recombinant human chorionic gonadotropin Recombinant Luteinizing Hormone or gonadotropin releasing Hormone gnrh agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with Recombinant follicle stimulating Hormone and gnrh antagonist cotreatment
The Journal of Clinical Endocrinology and Metabolism, 2003Co-Authors: Nicole G M Beckers, K Diedrich, R Felberbaum, Ernest Loumaye, Nick S Macklon, Marinus J C Eijkemans, Michael Ludwig, Shelly Bustion, Bart C J M FauserAbstract:Replacing GnRH agonist cotreatment for the prevention of a premature rise in LH during ovarian stimulation for in vitro fertilization (IVF) by the late follicular phase administration of GnRH antagonist may render supplementation of the luteal phase redundant, because of the known rapid recovery of pituitary function after antagonist cessation. This randomized two-center study was performed to compare nonsupplemented luteal phase characteristics after three different strategies for inducing final oocyte maturation. Forty patients underwent ovarian stimulation using Recombinant (r-)FSH (150 IU/d, fixed) combined with a GnRH antagonist (antide; 1 mg/d) during the late follicular phase. When at least one follicle above 18 mm was observed, patients were randomized to induce oocyte maturation by a single injection of either r-human (h)CG (250 μg) (n = 11), r-LH (1 mg) (n = 13), or GnRH agonist (triptorelin; 0.2 mg) (n = 15). Retrieved oocytes were fertilized by either IVF or intracytoplasmatic sperm injection,...
Yingpu Sun - One of the best experts on this subject based on the ideXlab platform.
-
Recombinant Luteinizing Hormone supplementation in women undergoing in vitro fertilization intracytoplasmic sperm injection with gonadotropin releasing Hormone antagonist protocol a systematic review and meta analysis
Reproductive Biology and Endocrinology, 2014Co-Authors: Yujing Xiong, Wei Dai, Meixiang Zhang, Xiao Bao, Yingpu SunAbstract:The objective of this meta-analysis is to assess the impact of LH supplementation in women undergoing in vitro fertilization/ intracytoplasmic sperm injection (IVF/ICSI) with gonadotropin releasing Hormone (GnRH) antagonist protocol. No significant difference in outcomes between LH supplementation and r-FSH alone in women undergoing IVF/ICSI with GnRH antagonist protocol is currently present, and further studies are necessary for more solid conclusions on pregnancy likelihood to be drawn.
-
Recombinant Luteinizing Hormone priming in early follicular phase for women undergoing in vitro fertilization: systematic review and meta-analysis.
Journal of International Medical Research, 2014Co-Authors: Keyan Wang, Yingpu SunAbstract:ObjectivesTo investigate the effect of Recombinant human Luteinizing Hormone supplementation (rLH priming) during the early follicular phase on in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) outcomes.MethodsIn order to evaluate available evidence regarding the efficacy of rLH priming in IVF/ICSI procedures, a systematic review and meta-analysis was preformed. Searches were conducted on MEDLINE®, EMBASE and the Cochrane Database of Clinical Trials without language limitation, but were restricted to randomized controlled trials (RCTs).ResultsThree RCTs including 346 patients were included in this meta-analysis, which demonstrated that rLH priming did not increase ongoing pregnancy rate. Although less Recombinant follicle-stimulating Hormone (rFSH) was required and the oestradiol level was higher on the day of human chorionic gonadotropin administration in the rLH priming group, the numbers of oocytes retrieved and embryos produced were comparable between patients treated with rLH p...